Takeda acquires Millennium

When I profiled Millennium Pharmaceuticals' chief scientific officer, Joe Bolen, in last month's issue of __The Scientist,__ he described some amusing airport foibles that had taken place during a linkurl:recent trip to Japan.;http://www.the-scientist.com/article/display/54340/ Now the whole company is going to Japan - at least on paper. Today, Millennium Pharmaceuticals, one of the first genomics companies in the US, was linkurl:acquired;http://investor.millennium.com/phoenix.zhtml?c=80159&p=ir

By | April 10, 2008

When I profiled Millennium Pharmaceuticals' chief scientific officer, Joe Bolen, in last month's issue of __The Scientist,__ he described some amusing airport foibles that had taken place during a linkurl:recent trip to Japan.;http://www.the-scientist.com/article/display/54340/ Now the whole company is going to Japan - at least on paper. Today, Millennium Pharmaceuticals, one of the first genomics companies in the US, was linkurl:acquired;http://investor.millennium.com/phoenix.zhtml?c=80159&p=irol-newsArticle&ID=1127852&highlight= by Takeda Pharmaceuticals, Japan's largest pharma company, for a whopping $8.8 billion dollars. Although Millennium will become a wholly owned subsidiary, the company will continue its operations in Cambridge Massachusetts.

Popular Now

  1. Henrietta Lacks’s Family Seeks Compensation
  2. Broad Wins CRISPR Patent Interference Case
    Daily News Broad Wins CRISPR Patent Interference Case

    The USPTO’s Patent Trial and Appeal Board has ruled in favor of the Broad Institute of MIT and Harvard retaining intellectual property rights covered by its patents for CRISPR gene-editing technology.

  3. Humans Never Stopped Evolving
    Features Humans Never Stopped Evolving

    The emergence of blood abnormalities, an adult ability to digest milk, and changes in our physical appearance point to the continued evolution of the human race.

  4. Abundant Sequence Errors in Public Databases
Business Birmingham